Bluesight Launches Prism, an AI Platform Built for Health Systems, Debuting with Prism Assistant By Adam Rosenberg Prism Assistant, the first product within Bluesight’s new AI platform, is now available in ControlCheck and cuts time spent on drug diversion analysis by...
Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies Phase 1 study builds on early signals of anti-tumor activity in patients with refractory T and B cell lymphomas Ipsoprubart, a first-in-class...
STAR THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE AND BREAKTHROUGH THERAPY DESIGNATIONS FOR VGA039 IN VON WILLEBRAND DISEASE PROPHYLAXIS VGA039 is a once monthly, subcutaneously self-administered investigational therapy for the treatment of bleeding disorders,...
MemorialCare Heart & Vascular Institute Becomes First Hospital in Los Angeles County to Offer Cleerly AI-Powered Heart Disease Analysis, Quantifying Total Plaque Volume and Soft Plaque Systemwide launch brings AI powered assessment to Coronary CTA’s to...
Cleerly AI-QCT Demonstrates High Agreement With Invasive IVUS in INVICTUS Registry Multicenter INVICTUS Registry Demonstrates Strong Correlation Between Noninvasive AI-QCT and Invasive IVUS for Coronary Plaque Quantification March 20, 2026 (DENVER, CO) – Cleerly, a...
Recent Comments